The aim of the study was to investigate whether or not there is a significant relationship between varicocele and SFJ insufficiency. This study included 200 men with (study group) and 200 men without (control group) primary varicocele which was initially diagnosed by observation during the Valsalva manoeuver. Subsequently, scrotal and lower extremity venous Doppler ultrasonography (USG) was performed by a senior radiologist, and participants with testicular veins >3.0 mm in diameter and reverse blood flow were determined to have varicocele. SFJ insufficiency was defined as retrograde flow in the SFJ of longer than 0.5 s. Retrograde venous flow in the pampiniform plexus was determined 3.5% (study) versus 0.0% (control) and 77.0% (study) versus 0.0% (control) in the right testis and left testis, respectively, and bilaterally at 11.5% (study) versus 0.0% (control). The presence of SFJ insufficiency was also found to be higher in the study group than in the control group (unilaterally: 26.0% versus 15.0%; bilaterally: 14.0% versus 5.0%). The current study demonstrates a statistically significant relationship between varicocele and SFJ insufficiency and supports the argument that varicocele is not a local disease and may be attributable to a systemic vascular insufficiency. Additional studies with larger series are needed to further elucidate this topic.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/and.13820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Apixaban to Prevent Covert Infarcts After Cryptogenic Stroke in Patients With Atrial Cardiopathy: A Secondary Analysis of the ARCADIA Randomized Clinical Trial.
JAMA Neurol
January 2025
Department of Neurology, UAB Heersink School of Medicine, University of Alabama at Birmingham, Birmingham.
Importance: In the Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke (ARCADIA) randomized clinical trial, anticoagulation did not prevent recurrent stroke among patients with a recent cryptogenic stroke and atrial cardiopathy. It is unknown whether anticoagulation prevents covert infarcts in this population.
Objective: To test the use of apixaban vs aspirin for prevention of nonlacunar covert infarcts after cryptogenic stroke in patients with atrial cardiopathy.
Flush Endovenous Laser Ablation (fEVLA) in the Treatment of Lower Limb Venous Insufficiency a Systematic Review and Meta-Analysis.
Ann Vasc Surg
December 2024
Department of Vascular Surgery, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
Background: To assess the safety and efficacy of flush endovenous laser ablation (fEVLA) in the treatment of chronic venous insufficiency (CVI).
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review aiming to identify studies published from inception to March 2024 was conducted. The investigation covered single-arm studies and studies comparing fEVLA to standard EVLA (sEVLA).
Feasibility and Safety of Flush Endovenous Thermal Ablation of the Great Saphenous Vein with Consecutive Foam Sclerotherapy of Saphenofemoral Junction Tributaries: A Single-Center Experience.
J Clin Med
November 2024
Department of Vascular Surgery, Jun's Vascular Clinic, Busan 47256, Republic of Korea.
Blood flow from the saphenofemoral junction(SFJ) tributaries may cause recurrence of varicose veins. Flush occlusion is defined as the total occlusion of the great saphenous vein(GSV) right to the saphenofemoral junction. The purpose of this study was to evaluate the efficacy and safety of flush endovenous thermal ablation with saphenofemoral junction tributary occlusion.
View Article and Find Full Text PDFBurden of Cardio-Cerebrovascular and Renal Diseases Attributable to Systolic Hypertension in France in 2021.
Hypertension
February 2025
Direction des maladies non transmissibles, Santé publique France, Saint-Maurice, France (C.G., A.G., M.J.T., V.O.).
Background: Hypertension is the most common chronic disease and a major modifiable risk factor for cardio-cerebrovascular and renal diseases. This study estimated the national burden of hypertension, defined as systolic blood pressure ≥140 mm Hg, on morbidity and mortality in 2021 in France.
Methods: For all diseases causally associated with hypertension (cardiovascular diseases, chronic kidney diseases, and dementia), the number and proportion of cases attributable to hypertension in adults aged ≥35 years were estimated using population attributable fractions.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Lancet Diabetes Endocrinol
August 2024
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. Electronic address:
Article Synopsis
- SGLT2 inhibitors and GLP-1 receptor agonists both have positive effects on cardiovascular and kidney health in patients with type 2 diabetes, leading to a study comparing their benefits when used together or separately.
- A meta-analysis from various trials showed that SGLT2 inhibitors effectively reduced risks of major cardiovascular events and kidney disease progression for patients whether or not they were taking GLP-1 receptor agonists.
- The consistency of these benefits across different outcomes indicates that SGLT2 inhibitors can be beneficial for all diabetic patients, regardless of GLP-1 receptor agonist usage.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!